Pharmaceuticals 11 February 2026 - 12 February 2026

Olema Pharmaceuticals Shares Sink More Than 40% After Roche Trial Miss
···

Olema Pharmaceuticals Shares Sink More Than 40% After Roche Trial Miss

Olema Pharmaceuticals shares fell over 40% Monday after Roche’s breast cancer drug giredestrant failed to meet its main goal in a late-stage trial. Investors viewed the setback as a negative signal for Olema’s lead drug, palazestrant, which is in Phase 3 studies. Roche said the trial showed no significant improvement in progression-free survival. Olema ended September with $329 million in cash and expects top-line data in late 2026.
March 9, 2026
Viking Therapeutics stock (VKTX) slips premarket as Phase 3 obesity pill timeline comes into focus
···

Viking Therapeutics stock (VKTX) slips premarket as Phase 3 obesity pill timeline comes into focus

Viking Therapeutics shares fell 0.7% to $28.55 in premarket trading Thursday after outlining plans to advance its oral obesity drug VK2735 into Phase 3 trials in the third quarter of 2026. The company completed enrollment for a Phase 3 injectable VK2735 study and reported a fourth-quarter net loss of $157.7 million, ending 2025 with $706 million in cash and equivalents.
February 12, 2026
1 2